nivolumab
Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.
Drug Monograph
 Nivolumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
 Nivolumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)   Nivolumab - Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck, which is Platinum Resistant or Refractory
 Nivolumab - Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck, which is Platinum Resistant or Refractory   Nivolumab - Relapsed Classical Hodgkin Lymphoma (cHL) Post-Autologous Stem Cell Transplant (ASCT) or ASCT Ineligible
 Nivolumab - Relapsed Classical Hodgkin Lymphoma (cHL) Post-Autologous Stem Cell Transplant (ASCT) or ASCT Ineligible   Nivolumab - Advanced or Metastatic Non-Small Cell Lung Cancer
 Nivolumab - Advanced or Metastatic Non-Small Cell Lung Cancer   Nivolumab plus Ipilimumab - Advanced Malignant Pleural Mesothelioma
 Nivolumab plus Ipilimumab - Advanced Malignant Pleural Mesothelioma   Nivolumab plus Ipilimumab - In Combo with Platinum Doublet Chemo for First Line Metastatic or Recurrent NSCLC
 Nivolumab plus Ipilimumab - In Combo with Platinum Doublet Chemo for First Line Metastatic or Recurrent NSCLC   Nivolumab - First-line Treatment of Advanced Gastric Esophageal and Esophagogastric Junction Adenocarcinoma
 Nivolumab - First-line Treatment of Advanced Gastric Esophageal and Esophagogastric Junction Adenocarcinoma   Nivolumab - Adjuvant Treatment of Completely Resected Esophageal or Esophagogastric Junction Cancer
 Nivolumab - Adjuvant Treatment of Completely Resected Esophageal or Esophagogastric Junction Cancer   Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma
 Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma   Nivolumab - Advanced or Metastatic Renal Cell Carcinoma and Prior mTOR Inhibitor
 Nivolumab - Advanced or Metastatic Renal Cell Carcinoma and Prior mTOR Inhibitor   Nivolumab - Advanced or Metastatic Renal Cell Carcinoma and No Prior mTOR Inhibitor
 Nivolumab - Advanced or Metastatic Renal Cell Carcinoma and No Prior mTOR Inhibitor   Nivolumab - Adjuvant Treatment of Urothelial Carcinoma
 Nivolumab - Adjuvant Treatment of Urothelial Carcinoma   Nivolumab - Neoadjuvant Treatment for Non-Small Cell Lung Cancer
 Nivolumab - Neoadjuvant Treatment for Non-Small Cell Lung Cancer   Nivolumab - In Combination with Cabozantinib for First Line Advanced or Metastatic Renal Cell Carcinoma
 Nivolumab - In Combination with Cabozantinib for First Line Advanced or Metastatic Renal Cell Carcinoma   Nivolumab plus Ipilimumab - (Neo)adjuvant Resectable Macroscopic Stage III Melanoma
 Nivolumab plus Ipilimumab - (Neo)adjuvant Resectable Macroscopic Stage III Melanoma   Nivolumab - Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanoma
 Nivolumab - Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanoma   Nivolumab - Adjuvant Treatment for Completely Resected Stage III or IV Melanoma
 Nivolumab - Adjuvant Treatment for Completely Resected Stage III or IV MelanomaPatient Info Sheet
What it is used for
- For treating many types of cancers such as melanoma (skin), lung, renal cell (kidney), colorectal, liver, head and neck, Hodgkin lymphoma, mesothelioma and others
- Nivolumab is an immunotherapy drug. For more information on immunotherapy, click here.
